about
Recent developments in osteogenesis imperfectaThe management of osteoporosis in children.Osteoclasts: more than 'bone eaters'.Two years' experience with denosumab for children with osteogenesis imperfecta type VIClinical guidelines for the management of craniofacial fibrous dysplasia.Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANKA randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.Rapid skeletal turnover in a radiographic mimic of osteopetrosis.Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.[Fibrous dysplasia: overview]Fibrous dysplasia and cherubismBone health in cerebral palsy and introduction of a novel therapy.Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.Effects of denosumab treatment and discontinuation on human growth plates.Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia.Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.Causes, mechanisms and management of paediatric osteoporosis.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects.Treatment Challenges with Benign Bone Tumors of the Orbit.Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.Fibrous dysplasia of bone: craniofacial and dental implications.Denosumab for the treatment of giant cell tumor of the bone.Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review.Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.Long-term health outcomes of adults with McCune-Albright syndrome.Treatment of Polyostotic Fibrous Dysplasia of the Thoracic Spine with Intravenous Pamidronate: Result from 9 Months Follow Up.Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa.Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases.Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.Our experience in the surgical management of craniofacial fibrous dysplasia: what has changed in the last 10 years?Expression of an active Gαs mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance.Monoclonal antibodies for treating osteoporosis.Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases.The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur.Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.Increased bone turnover, osteoporosis, progressive tibial bowing, fractures, and scoliosis in a patient with a final-exon SATB2 frameshift mutation.
P2860
Q26781674-F6B2C9B0-E9D1-4684-A6DA-7E393C9E6583Q30251490-8B318E7C-6E5D-43CD-AC27-820C548D527AQ33993757-1E0DF516-04E1-4DC2-9357-77EC2D5FAAC4Q34269289-C9341566-0B12-4226-8BBA-FBC06524043BQ34277729-4BE85F4D-9A57-401F-8DEB-A6C128E87F02Q34307564-D7CF4192-71EE-46E0-8A17-0FCA96B75F01Q34429461-5B0E11F0-115F-4E99-996F-B0750E6525A9Q35343702-8258C296-2348-4CA9-A91C-A18CA61422CAQ36013086-F32CC176-45AE-4FE6-9451-8F2036F0F4FAQ36031410-063977AA-4D18-46E8-9A34-26AB74232208Q36570392-C9A2F8FF-6478-4554-BC6B-E275B476C36AQ36931532-4685F3F3-820A-4167-90E3-0DFB41B3AB74Q37365056-1B375616-A34C-4172-B08E-E53B03A1004DQ37384560-8AB5D06D-CB4C-4538-918D-3C9438446DA6Q37616880-F7F2A2B9-EA4B-499B-9837-5F9CCDAD7252Q37653297-79965148-85F5-4152-880C-AAE07EA5C3C4Q38040123-DC529C56-AE21-4115-8CEE-53E70901B4A1Q38099517-AD5E3398-27C2-4973-A34E-AA0D89F950F0Q38712724-E5447CA3-4079-424E-B475-21DED57C1CD0Q38753349-7B5EFA1B-1E6A-4C71-905E-DA21A2B96BD4Q38832700-21BD5440-89F2-42F6-A602-3622AE3B085AQ38834385-0ABC5D7E-D414-4F2C-9EE0-AF6549468231Q38918970-C76AADD5-5019-4382-9427-E4A7C7380A45Q38919235-201E8D2A-0822-4D3A-8DF0-A54B5DB91205Q38986160-5CAD06EE-F6AA-4FB5-B879-70283807D658Q38990116-9EF0BFB9-977D-4FFD-8BB9-9B812DBE340FQ39214226-D96F040B-5EA8-424C-BCB1-CBC8F2EC157DQ39377609-289D12FC-CF13-4F9D-BEFB-9A778594E377Q39429965-DA06956D-F7CA-4BDD-BB44-23E6F7F18894Q42116605-14219819-5FA8-476E-9737-C572C549F7E3Q43973225-572EB4B1-BDC4-4AE5-89BD-60DC165105B9Q45980581-6525DC8E-AF77-43B4-883B-1680914EFF8DQ46004364-72444B20-0B16-47AB-AD3D-14050C917803Q47127429-D6E99393-8F81-468F-B48C-8B693BFA0294Q47250948-F8978997-FB8D-4145-96E3-0A9C1F6938A1Q47638169-8E5989E6-622D-4000-8EBF-5F90A4B6081CQ48331949-37A5A418-E625-4E26-975B-91488E7A1E76Q50060345-0543E696-6009-4764-9379-8A2F07C46679Q51065526-CC1A21A5-DC45-4B7A-AC03-2C89F6CB9204Q52127982-5B9720E1-E63F-4AED-BB3D-EE34DA3F530A
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Denosumab treatment for fibrous dysplasia.
@ast
Denosumab treatment for fibrous dysplasia.
@en
type
label
Denosumab treatment for fibrous dysplasia.
@ast
Denosumab treatment for fibrous dysplasia.
@en
prefLabel
Denosumab treatment for fibrous dysplasia.
@ast
Denosumab treatment for fibrous dysplasia.
@en
P2093
P2860
P356
P1476
Denosumab treatment for fibrous dysplasia.
@en
P2093
Alfredo A Molinolo
Alison M Boyce
Carol Bassim
Christine E Chamberlain
Frances A Farley
Josephine Z Kasa-Vubu
Marilyn H Kelly
Michael T Collins
Michelle Ellsworth
P2860
P304
P356
10.1002/JBMR.1603
P577
2012-07-01T00:00:00Z